Prostate cancer
(PCa) is the second most lethal cancer in American men with a high incidence
rate. Current method of PCa screening is not specific to aggressive cancer
type, which results in overtreatment with serious adverse effects. We developed
a MRI contrast agent, ZD2-Gd(HP-DO3A), that targets to overexpressed
extradomain-B in aggressive PCa. Our result showed an increased sensitivity for MRI detection of
aggressive PCa using ZD2-Gd(HP-DO3A),
compared with the clinical control agent ProHance®. This contrast agent
can potentially facilitate accurate risk stratification and clinical management
of PCa.
